$423 million, Heng Rui! Gifenib Drug Research Report

Guide: The original manufacturer's global sales for the product in 2019 will be approximately $423 millionGuide:June 4, Hengrui's Jifeiteni was approved for listing, so far, in addition to the original research manufacturers, the domestic has Qilu, Zhengda Tianqing, Hunan Collum, Hengrui 4 approved for listing, and Jiangsu Tianshili and other 6 declared productionAccording to the evaluationpharma database, the global sales of the original research plant in 2019 will be approximately $423 millionThis issue will present basic research information on the drugcatalog:1, Summary Information2, Drug Overview3, API Information4, Pharmacological Effect5, China Listing6, U.SListing7, EU Listing8, Japan Listing9, Major Listed Countries10, Global Sales11, China Registered12 Drug specifications13, global clinical trials14, domestic winning information15, domestic patent status16, world patent status17, more detailed1, abstract information2, drug overviewGefitinib developed by AstraZeneca (AZ), It was approved by the Japan Pharmaceutical Medical DeviceS Agency (PMDA) on July 5, 2002, and then on May 5, 2003 by the U.SFood and Drug Administration (FDA), and then on June 24, 2009 by the European Medicines Agency (EMA) approved by AstraZeneca for saleGifitinib is the first epidermal growth factor receptor (EGFR) tyrosine kinase selective inhibitorSuitable for single drug continuing to treat platinum and Dositatha chemotherapy failed locally advanced or metastatic non-small cell lung cancerIressa is an oral tablet containing 250 mg of gifitini per tablet, and the recommended dose is 250 mg per adult daily3, API InformationStructure: Chemical Name: N-(3-chloro-4-fluorophenyl)-7-methoxy-6-3-(morpholin-4-yl) propoxy- quinazolin-4-amine
CAS registration number: 184475-35-2 molecular : C2222 CIFN4O3 Molecular Weight : 446.91 4, Pharmacological Action ATC Classification: L01XE02 Anti-Tumor Drugs and Immuno-Regulating Drugs- Anti-Tumor Drugs-Other Anti-Tumor Drugs-Protein Kinase Inhibitors-Gfenib Action Target: EGFR
Reference Target: Epidermitor
Inhibits the epidermal growth factor (EGFR) tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme Tha ei a' sy'n ee eGFR tyrosine kinase yn activated the ras trans-signal cascade is inhibited; And malignant cells are ar inhibited Gefitinib is the first selective put of the EGFR tyrosine kinase is also sys sys to as Her1 or ErbB-1 EGFR is overexpressed in the cells of the type of man man carcinomas - for example in lung and cancer Overly led to the op-edifle of the apoptotic ras signal trans-sports cascade, theoly acer to the headed cell Indications: Metastaticnonsmall cellcelllungcancer; Ovarytumor
5, China Listing (18 Registration Approvals) 6, US Listing (2 Registration Approvals) 7, EU Listing (2 Registration Approvals) 8, Japan Listing (9 Registration Approvals) 9 The main listed countries /region (20 registration approvals) 10, global sales 11, China's registration declaration
According to the drug registration and acceptance database shows that up to now CDE has accepted a total of 93 gifiedini registration acceptance numbers, of which 60 tablets, 33 raw materials 12, drug instructions pharmaceutical intelligence data enterprise version of the drug database shows that the current global gifitinib a total of 12 instructions Note: If you need to download, enter the drug intelligence data, in the Drug Reporting Office for instructions download 13, global clinical trials (457) Note: due to the large number of data, here only some of the data, details into the drug data - drug report for review 14, domestic winning bid information (300) 15, domestic patent status (161) 16, world patent status (5081) 17, more details data sources: pharmaceutical data enterprise version of the drug database because the full text of the report is large, the article only shows part of the content For more information, click on the link view it directly